In summary, the PI3K/AKT/mTOR pathway is a critical target in ovarian cancer therapy, and the combination of PI3K inhibitors with PARP inhibitors shows promise in some ovarian cancer patients. Here, PARP1 is linked to ovarian carcinoma.